RecruitingNCT06523738

Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)

Association of Left Atrial Volume Changes After Cardioversion and Recurrence of Atrial Fibrillation After Radiofrequency Ablation in Patients With Persistent Atrial Fibrillation


Sponsor

The Second Affiliated Hospital of Chongqing Medical University

Enrollment

100 participants

Start Date

Jul 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion and the recurrence rate of atrial fibrillation following radiofrequency ablation.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients with estabolished diagnosis of Persistent Atrial Fibrillation during past 6 mnths.
  • LAD brfore entering the two cohorts is more than 40mm, and less than 50mm.
  • Pharmacological or electrical cardioversion has be performed successfully.
  • At least two echocardiograms were performed before and 3-6 months after cardioversion., and confirm the status of LAD (Reversal, unchange, enlargment).
  • Patients have given informed consent.

Exclusion Criteria3

  • Prior radiofrequency ablation treatment for atrial fibrillation
  • Prior cardiac surgical procedures
  • Individuals with cognitive impairments who are unable to give informed consent

Interventions

DIAGNOSTIC_TEST1. electrical/pharmacological cardioversion. 2.pulmonary vein isolation

1\. electrical/pharmacological cardioversion. 2. pulmonary vein isolation for persistent atrial fibrillation


Locations(1)

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06523738